What is William Blair's Estimate for Genmab A/S Q1 Earnings?

Genmab A/S (NASDAQ:GMAB - Free Report) - Equities researchers at William Blair issued their Q1 2026 EPS estimates for shares of Genmab A/S in a research note issued on Tuesday, March 18th. William Blair analyst M. Phipps forecasts that the company will post earnings per share of $0.37 for the quarter. William Blair has a "Outperform" rating on the stock. The consensus estimate for Genmab A/S's current full-year earnings is $1.45 per share. William Blair also issued estimates for Genmab A/S's Q2 2026 earnings at $0.57 EPS, Q3 2026 earnings at $0.62 EPS and Q4 2026 earnings at $0.67 EPS.

Other equities analysts have also issued research reports about the stock. Sanford C. Bernstein upgraded shares of Genmab A/S from a "strong sell" rating to a "hold" rating in a research note on Friday, December 20th. Leerink Partnrs upgraded shares of Genmab A/S from a "hold" rating to a "strong-buy" rating in a report on Thursday, February 13th. HC Wainwright reiterated a "buy" rating and issued a $50.00 target price on shares of Genmab A/S in a research note on Thursday, January 23rd. Truist Financial lowered their price target on Genmab A/S from $50.00 to $45.00 and set a "buy" rating on the stock in a research note on Tuesday, March 11th. Finally, BNP Paribas upgraded Genmab A/S from a "strong sell" rating to a "hold" rating in a research report on Tuesday, February 11th. Four equities research analysts have rated the stock with a hold rating, eight have assigned a buy rating and one has assigned a strong buy rating to the stock. According to data from MarketBeat, the stock has a consensus rating of "Moderate Buy" and a consensus target price of $41.33.

Remove Ads

Genmab A/S Stock Down 0.4 %

NASDAQ GMAB traded down $0.08 during trading on Wednesday, hitting $19.76. The company's stock had a trading volume of 1,122,331 shares, compared to its average volume of 916,237. Genmab A/S has a 52 week low of $18.64 and a 52 week high of $31.02. The firm has a market cap of $13.08 billion, a P/E ratio of 11.36, a price-to-earnings-growth ratio of 2.65 and a beta of 0.98. The firm has a 50 day moving average price of $21.04 and a 200 day moving average price of $22.15.

Genmab A/S (NASDAQ:GMAB - Get Free Report) last issued its quarterly earnings results on Wednesday, February 12th. The company reported $0.57 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.28 by $0.29. Genmab A/S had a return on equity of 16.78% and a net margin of 36.30%.

Hedge Funds Weigh In On Genmab A/S

Hedge funds have recently modified their holdings of the stock. EverSource Wealth Advisors LLC grew its position in Genmab A/S by 295.3% in the fourth quarter. EverSource Wealth Advisors LLC now owns 1,257 shares of the company's stock valued at $26,000 after acquiring an additional 939 shares during the period. Lindbrook Capital LLC boosted its stake in shares of Genmab A/S by 105.4% in the 4th quarter. Lindbrook Capital LLC now owns 1,851 shares of the company's stock valued at $39,000 after purchasing an additional 950 shares in the last quarter. GAMMA Investing LLC grew its holdings in shares of Genmab A/S by 96.6% in the 4th quarter. GAMMA Investing LLC now owns 2,139 shares of the company's stock worth $45,000 after purchasing an additional 1,051 shares during the last quarter. Barclays PLC increased its position in shares of Genmab A/S by 1,072.8% during the 4th quarter. Barclays PLC now owns 2,498 shares of the company's stock worth $52,000 after purchasing an additional 2,285 shares in the last quarter. Finally, Cromwell Holdings LLC lifted its holdings in Genmab A/S by 656.8% during the 4th quarter. Cromwell Holdings LLC now owns 2,876 shares of the company's stock valued at $60,000 after purchasing an additional 2,496 shares during the last quarter. 7.07% of the stock is owned by institutional investors and hedge funds.

Genmab A/S Company Profile

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.